-0.86%
3.18%
4.05%
2.12%
22.78%
-24.80%
-7.33%
AI Spotlight on DIA
Company Description
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China.The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample.It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections.
The company was founded in 1968 and is headquartered in Saluggia, Italy.
Market Data
| Last Price | 103.7 |
| Change Percentage | -0.86% |
| Open | 104.4 |
| Previous Close | 104.6 |
| Market Cap ( Millions) | 5529 |
| Volume | 90429 |
| Year High | 112.35 |
| Year Low | 82.72 |
| M A 50 | 102.78 |
| M A 200 | 101.51 |
Financial Ratios
| FCF Yield | 3.80% |
| Dividend Yield | 1.11% |
| ROE | 10.67% |
| Debt / Equity | 63.68% |
| Net Debt / EBIDTA | 321.88% |
| Price To Book | 3.42 |
| Price Earnings Ratio | 32.74 |
| Price To FCF | 26.34 |
| Price To sales | 4.76 |
| EV / EBITDA | 23.92 |
News
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Diagnostic Kits
Expected Growth : 7 %
What the company do ?
Diagnostic Kits from DiaSorin S.p.A. are in vitro diagnostic devices used to detect and quantify various analytes, such as infectious diseases, hormones, and tumor markers, in human samples.
Why we expect these perspectives ?
DiaSorin's Diagnostic Kits segment growth is driven by increasing demand for molecular diagnostics, particularly in infectious disease testing, and the company's strong product portfolio, including its Liaison and Vet turbidimetry platforms. Additionally, strategic acquisitions, expansion into emerging markets, and growing adoption of point-of-care testing are contributing to the 7% growth.
Diasorin S.P.A. Products
| Product Range | What is it ? |
|---|---|
| LIAISON | A family of fully automated chemiluminescence analyzers for clinical diagnostics |
| ETI-Max | A range of ELISA (Enzyme-Linked Immunosorbent Assay) kits for the detection of infectious diseases |
| Sorin 100 | A fully automated analyzer for the detection of infectious diseases |
| LIAISON XL | A high-throughput, fully automated chemiluminescence analyzer for clinical diagnostics |
| DiaSorin Molecular | A range of molecular diagnostic products for the detection of infectious diseases |
DiaSorin S.p.A.'s Porter Forces
Threat Of Substitutes
DiaSorin S.p.A. operates in the in vitro diagnostics industry, where substitutes are limited. However, the company faces competition from other diagnostic companies, which could lead to a moderate threat of substitutes.
Bargaining Power Of Customers
DiaSorin S.p.A.'s customers are primarily healthcare providers and laboratories, which have limited bargaining power due to the company's strong brand reputation and product offerings.
Bargaining Power Of Suppliers
DiaSorin S.p.A. relies on a network of suppliers for raw materials and components. While the company has some bargaining power, suppliers also have some leverage due to the specialized nature of the industry.
Threat Of New Entrants
The in vitro diagnostics industry has high barriers to entry, including regulatory hurdles and significant R&D investments. This limits the threat of new entrants and gives DiaSorin S.p.A. a competitive advantage.
Intensity Of Rivalry
The in vitro diagnostics industry is highly competitive, with several established players competing for market share. DiaSorin S.p.A. faces intense rivalry from companies such as Roche, Siemens, and Abbott.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 43.48% |
| Debt Cost | 3.95% |
| Equity Weight | 56.52% |
| Equity Cost | 4.64% |
| WACC | 4.34% |
| Leverage | 76.94% |
DiaSorin S.p.A. : Quality Control
DiaSorin S.p.A. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IPN.PA | Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors … |
| QIA.DE | QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for … |
| ERF.PA | Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, … |
| SYAB.DE | SYNLAB AG provides clinical laboratory and medical diagnostic services for insurance companies, hospitals, pharmacies, national health organizations, practicing doctors, clinics, patients, governments, and corporations primarily in Europe. The company offers … |
| BIM.PA | bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ipsen
A-Score
1-Year Total Return ->
🥈
Synlab
A-Score
1-Year Total Return ->
🥉
DiaSorin
A-Score
1-Year Total Return ->
4
Qiagen
A-Score
1-Year Total Return ->
5
bioMérieux
A-Score
1-Year Total Return ->
6
